C. diff. Spores and More

The majority of C. difficile cases are caused by the unintended consequences of antibiotic therapy to the gut microbiome. Intravenous (IV) antibiotics excreted to the gut often wipe out the natural balance of microflora, which can lead to recurring diarrhea and perforation of the intestinal wall, with potentially fatal outcomes. Co-administered with IV antibiotics, Synthetic Biologics’ product candidate, SYN-004, is designed to be a preventive therapy intended to protect the gut microbiome by degrading IV antibiotics, thereby preventing the onset of C. difficile infection. Synthetic Biologics, Inc.’s Lewis Barrett, BS, MBA, Senior Vice President, Commercial Strategy and Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs will discuss the novel point-of-care preventive approach, the clinical development pathway and the potential of the Company’s lead pathogen-specific product candidate, SYN-004.

Lee Jones, Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Rebiotix is developing a new category of biologic drugs that use live human-derived organisms to treat disease. Lead candidate RBX2660 (microbiota suspension) is currently undergoing clinical study for recurrent C. diff. infection. Glenn Taylor is the Microbiologist at the Taymount Clinic just outside London in the UK. He has spent five years researching the commensal colonization of bacteria in the human digestive system. Listen in as both guests discuss the Fecal or Faecal Microbiota Transplant (FMT),also known as Microbiota Restoration Therapy to treat

recurrent C. diff. infections and more – Research to Clinical

Professor Sheridan, C. diff. Survivor and FMT Patient : Nancy Sheridan is a full time, Associate Professor at the Fashion Institute of Technology and a winner of the prestigious SUNY Chancellor’s Award for Excellence in Teaching. Professor Sheridan has been teaching since fall 2000 in the Fashion Merchandising Management Department within the School of Business and Technology. For the past seven years, she has also taught a Retail Merchandising course at the University of Pennsylvania, Wharton Business School to undergraduate and MBA students. In June of 2014, Nancy had surgery and contracted c.diff while in the hospital, suffered 5 c.diff reoccurrences from June to December 2014 in January she received a Fecal Microbiota Transplant and has been c diff free since.

The majority of C. difficile cases are caused by the unintended consequences of antibiotic therapy to the gut microbiome. Intravenous (IV) antibiotics excreted to the gut often wipe out the natural balance of microflora, which can lead to recurring diarrhea and perforation of the intestinal wall, with potentially fatal outcomes. Co-administered with IV antibiotics, Synthetic Biologics’ product candidate, SYN-004, is designed to be a preventive therapy intended to protect the gut microbiome by degrading IV antibiotics, thereby preventing the onset of C. difficile infection. Synthetic Biologics, Inc.’s Lewis Barrett, BS, MBA, Senior Vice President, Commercial Strategy and Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs will discuss the novel point-of-care preventive approach, the clinical development pathway and the potential of the Company’s lead pathogen-specific product candidate, SYN-004.

Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine.

Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines.

Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.

Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine.

Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines.

Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.

Key Scientific Researchers, Dr. Casey Theriot of University of Michigan will be discussing the latest research how C. difficile wreaks havoc on the guts of animals in a short time, and causes severe diarrhea and life-threatening disease in humans. and Dr. Matha Clokie of University of Leicester UK will also be discussing the most recent work in the are of C. difficile research.

Nancy C. Caralla, the C Diff Foundation's Founding Executive Director and Dr. Chandrabali Ghose, Chairperson of Research and Development introduce the first episode of C. diff. Spores and More. As advocates for C. diff. infection prevention, treatments, and environmental safety, we are excited to launch this cutting-edge new weekly radio show and what it means for our Foundation’s community worldwide.